**Supplementary Table 2. Purchase volume and growth rate of hepatitis B antiviral drugs from April 2018 to March 2021** **by region**

|  |  |  |  |
| --- | --- | --- | --- |
| Hepatitis B antiviral drugs | Volume (million DDDs) | Average | Cumulative |
| April 2018–March 2019 | April 2019–March 2020 | April 2020–March 2021 | GR (%) | GR (%) |
| North China | 65.18 | 112.98 | 144.88 | 50.79 | 122.29 |
| ETV  | 46.04 | 90.30 | 112.61 | 60.41 | 144.57 |
| TDF  | 6.82 | 15.10 | 24.39 | 91.51 | 257.77 |
| ADV  | 7.56 | 4.33 | 5.74 | -5.03 | -24.03 |
| LAM  | 3.57 | 2.37 | 1.50 | -35.17 | -57.99 |
| Ltd  | 1.19 | 0.89 | 0.64 | -26.51 | -46.00 |
| East China | 275.89 | 482.56 | 555.23 | 44.98 | 101.25 |
| ETV  | 195.76 | 381.19 | 431.36 | 53.94 | 120.35 |
| TDF  | 6.95 | 49.14 | 81.31 | 336.32 | 1070.07 |
| ADV  | 42.1 | 28.96 | 24.28 | -23.74 | -42.41 |
| LAM  | 24.73 | 19.33 | 15.31 | -21.32 | -38.09 |
| Ltd  | 6.29 | 3.94 | 2.96 | -31.05 | -52.86 |
| Central China | 74.29 | 93.08 | 125.70 | 30.17 | 69.21 |
| ETV  | 53.92 | 73.03 | 95.85 | 33.35 | 77.77 |
| TDF  | 3.28 | 8.64 | 19.86 | 146.50 | 504.84 |
| ADV  | 10.86 | 7.05 | 7.83 | -12.00 | -27.91 |
| LAM  | 5.40 | 3.93 | 1.99 | -38.23 | -63.05 |
| Ltd  | 0.82 | 0.43 | 0.16 | -55.58 | -80.90 |
| South China | 63.28 | 89.02 | 113.66 | 34.18 | 79.61 |
| ETV  | 47.73 | 70.01 | 80.29 | 30.69 | 68.23 |
| TDF  | 2.36 | 11.10 | 26.13 | 253.01 | 1007.64 |
| ADV  | 6.37 | 3.92 | 3.72 | -21.75 | -41.60 |
| LAM  | 3.75 | 1.58 | 1.38 | -35.23 | -63.21 |
| Ltd  | 3.07 | 2.42 | 2.14 | -16.46 | -30.44 |
| Southwest China | 58.35 | 99.36 | 124.58 | 47.83 | 113.50 |
| ETV  | 40.21 | 75.65 | 94.35 | 56.43 | 134.65 |
| TDF  | 4.80 | 13.82 | 22.63 | 125.89 | 371.66 |
| ADV  | 7.64 | 5.53 | 4.66 | -21.69 | -39.03 |
| LAM  | 4.60 | 3.49 | 2.33 | -28.62 | -49.26 |
| Ltd  | 1.11 | 0.87 | 0.61 | -25.80 | -45.15 |
| Northwest China | 25.71 | 50.23 | 56.07 | 53.51 | 118.11 |
| ETV  | 18.66 | 40.98 | 45.30 | 65.06 | 142.74 |
| TDF  | 1.67 | 4.50 | 8.03 | 123.82 | 380.42 |
| ADV  | 3.83 | 3.22 | 1.66 | -32.19 | -56.70 |
| LAM  | 1.29 | 1.34 | 0.94 | -13.04 | -27.26 |
| Ltd  | 0.25 | 0.19 | 0.14 | -24.98 | -43.72 |
| Northeast China | 36.14 | 44.04 | 49.44 | 17.07 | 36.81 |
| ETV  | 26.33 | 32.84 | 35.39 | 16.24 | 34.39 |
| TDF  | 3.60 | 7.41 | 10.99 | 76.97 | 204.97 |
| ADV  | 3.46 | 2.15 | 2.05 | -21.28 | -40.82 |
| LAM  | 2.13 | 1.33 | 0.81 | -38.51 | -62.20 |
| Ltd  | 0.61 | 0.32 | 0.21 | -40.93 | -65.59 |

Adefovir, ADV; DDD, defined daily dose; ETV, entecavir; GR, growth rate; LAM, lamivudine; Ltd, telbivudine; TDF, tenofovir disoproxil fumarate.

Note：North China include Beijing, Tianjin, Hebei, Shanxi and Inner Mongolia. East China included Shanghai, Shandong, Jiangsu, Anhui, Jiangxi, Zhejiang and Fujian. Central China included Hubei, Hunan and Henan. South China included Guangdong, Guangxi and Hainan. Southwest included Chongqing, Sichuan, Guizhou, Yunnan and Tibet. Northwest included Shanxi, Gansu, Qinghai, Ningxia and Xinjiang. Northeast included Heilongjiang, Jilin and Liaoning.